Background Among patients with B-cell chronic lymphoid leukemia, those with 13ql4 deletion have a favorable outcome. However, whether the percentage of cells with 13q- influences the prognosis or the biological characteristics of this disease is unknown. We analyzed the clinico-biological characteristics and outcome of patients with B-cell chronic lymphoid leukemia with loss of 13q as the sole cytogenetic aberration. Design and Methods Three hundred and fifty patients with B-cell chronic lymphoid leukemia were studied. Clinical data were collected and fluorescence in situ hybridization and molecular studies were carried out. In addition, a gene expression profile was obtained by microarray-based analysis. Results In 109 out of the 350 cases (31.1%) loss of 13q was the sole cytogenetic aberration at diagnosis. In the subgroup of patients with 80% or more of cells with loss of 13q (18 cases), the overall survival was 56 months compared with not reached in the 91 cases in whom less than 80% of cells had loss of 13q ($ < 0.0001). The variables included in the multivariate analysis for overall survival were the percentage of losses of 13ql4 (/?=0.001) and B symptoms (/?=0.007). The time to first therapy in the group with 80% or more vs. less than 80% of losses was 38 months vs. 87 months, respectively (/?=0.05). In the multivariate analysis the variables selected were unmutated status of IgVH (/?=0.001) and a high level of microglobulin (/?=0.003). Interestingly, these differences regarding overall survival and time to first therapy were also present when other cut-offs were considered. The gene expression profile of patients with a high number of losses in 13ql4 showed a high proliferation rate, downregulation of apoptosis-related genes, and dysregulation of genes related to mitochondrial functions. Conclusions Patients with B-cell chronic lymphoid leukemia with a high number of losses in 13ql4 as the sole cytogenetic aberration at diagnosis display different clinical and biological features: short overall survival and time to first therapy as well as more proliferation and less apop- tosis. A quantification of the number of cells showing a genetic abnormality should, therefore, be included in the study of the prognostic factors of B-cell chronic lymphoid leukemia.
Quantitative analysis of repetitive elements methylation in B-cell chronic lymphocytic leukemia / S. Fabris, V. Motta, V. Bollati, V. Pegoraro, G. Cutrona, L. Mosca, S. Matis, D. Ronchetti, M. Colombo, M. Gentile, M. Spriano, V. Callea, G. Festini, S. Molica, A. Cortelezzi, G. Lambertenghi Deliliers, F. Morabito, M. Ferrarini, P.A. Bertazzi, A. Baccarelli, A. Neri. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 94:2(2009), pp. 364-364. ((Intervento presentato al 14. convegno Congress of the European Hematology Association tenutosi a Berlino nel 2009 [10.3324/haematol.13862].
Quantitative analysis of repetitive elements methylation in B-cell chronic lymphocytic leukemia
S. Fabris;V. Bollati;D. Ronchetti;A. Cortelezzi;G. Lambertenghi Deliliers;P.A. Bertazzi;A. Neri
2009
Abstract
Background Among patients with B-cell chronic lymphoid leukemia, those with 13ql4 deletion have a favorable outcome. However, whether the percentage of cells with 13q- influences the prognosis or the biological characteristics of this disease is unknown. We analyzed the clinico-biological characteristics and outcome of patients with B-cell chronic lymphoid leukemia with loss of 13q as the sole cytogenetic aberration. Design and Methods Three hundred and fifty patients with B-cell chronic lymphoid leukemia were studied. Clinical data were collected and fluorescence in situ hybridization and molecular studies were carried out. In addition, a gene expression profile was obtained by microarray-based analysis. Results In 109 out of the 350 cases (31.1%) loss of 13q was the sole cytogenetic aberration at diagnosis. In the subgroup of patients with 80% or more of cells with loss of 13q (18 cases), the overall survival was 56 months compared with not reached in the 91 cases in whom less than 80% of cells had loss of 13q ($ < 0.0001). The variables included in the multivariate analysis for overall survival were the percentage of losses of 13ql4 (/?=0.001) and B symptoms (/?=0.007). The time to first therapy in the group with 80% or more vs. less than 80% of losses was 38 months vs. 87 months, respectively (/?=0.05). In the multivariate analysis the variables selected were unmutated status of IgVH (/?=0.001) and a high level of microglobulin (/?=0.003). Interestingly, these differences regarding overall survival and time to first therapy were also present when other cut-offs were considered. The gene expression profile of patients with a high number of losses in 13ql4 showed a high proliferation rate, downregulation of apoptosis-related genes, and dysregulation of genes related to mitochondrial functions. Conclusions Patients with B-cell chronic lymphoid leukemia with a high number of losses in 13ql4 as the sole cytogenetic aberration at diagnosis display different clinical and biological features: short overall survival and time to first therapy as well as more proliferation and less apop- tosis. A quantification of the number of cells showing a genetic abnormality should, therefore, be included in the study of the prognostic factors of B-cell chronic lymphoid leukemia.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
